Clinical Research Directory
Browse clinical research sites, groups, and studies.
Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease
Sponsor: Hoffmann-La Roche
Summary
This Phase 2, randomized, double-blind, multicenter, induction and maintenance study is designed to evaluate the safety and efficacy of Afimkibart (RO7790121, RVT-3101) in adult participants with moderate to severe active Crohn's disease.
Official title: A Phase 2, Multicenter, Double-blind, Two-arm Study of Subcutaneous RO7790121 for the Treatment of Subjects With Moderate to Severe Active Crohn's Disease
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
21
Start Date
2023-07-24
Completion Date
2030-12-31
Last Updated
2026-03-24
Healthy Volunteers
No
Conditions
Interventions
Afimkibart
Afimkibart will be administered during the Induction, Maintenance and OLE period.
Locations (11)
Digestive Health Specialists
Dothan, Alabama, United States
Medical Research Center of Connecticut, LLC
Hamden, Connecticut, United States
I.H.S Health Northwell Health
Kissimmee, Florida, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
Clinical Research Institute of Michigan
Chesterfield, Michigan, United States
AZ Delta
Roeselare, Belgium
CHU de Nantes
Nantes, France
Institut des MICI, Clinique Ambroise Paré
Neuilly-sur-Seine, France
CHRU de Nancy Brabois
Vandœuvre-lès-Nancy, France
Twoja Przychodnia-Szczecinskie Centrum Medyczne
Szczecin, Poland
WIP Warsaw IBD Point Profesor Kierkus
Warsaw, Poland